| Title: |
ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Multicenter French Study (START). |
| Authors: |
Korobelnik, Jean-François; Souied, Eric H; Oubraham, Hassiba; Razavi, Sam; Mauget-Faÿsse, Martine; Savel, Helene; Chene, Genevieve; Wolf, Sebastian |
| Source: |
Korobelnik, Jean-François; Souied, Eric H; Oubraham, Hassiba; Razavi, Sam; Mauget-Faÿsse, Martine; Savel, Helene; Chene, Genevieve; Wolf, Sebastian (2021). ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Multicenter French Study (START). Retina, 41(3), pp. 588-594. Wolters Kluwer 10.1097/IAE.0000000000002910 |
| Publisher Information: |
Wolters Kluwer |
| Publication Year: |
2021 |
| Collection: |
BORIS (Bern Open Repository and Information System, University of Bern) |
| Subject Terms: |
610 Medicine & health |
| Description: |
PURPOSE To assess early changes in spectral-domain optical coherence tomography during the loading phase with intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration. METHODS In this prospective, open-label, single-arm, multicenter study, patients with neovascular age-related macular degeneration, who were antivascular endothelial growth factor treatment-naïve, received three monthly initial doses of intravitreal aflibercept 2 mg. The primary outcome was the proportion of patients with dry spectral-domain optical coherence tomography at 12 weeks, defined as an absence of intraretinal edema, intraretinal cysts, subretinal fluid, and subretinal pigment epithelium fluid. RESULTS Fifty eyes of 50 patients were investigated. At 12 weeks, 34.0% (17/50) had dry spectral-domain optical coherence tomography. Marked reductions were observed for all other spectral-domain optical coherence tomography parameters. The mean macular central thickness fell significantly from 463.2 ± 184.3 µm at baseline to 288.9 ± 76.8 µm at Week 12 (P < 0.0001). The mean best-corrected visual acuity also improved significantly from 61.0 ± 16.0 letters at baseline to 66.6 ± 19.0 letters at Week 12 (P = 0.0006). CONCLUSION The anatomic and functional outcomes improved over the 12-week study period. All outcome variables peaked after the third aflibercept injection, confirming the benefit of three initial doses. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://boris.unibe.ch/153855/ |
| Availability: |
https://boris.unibe.ch/153855/1/ASSESSMENT_OF_EARLY_CHANGES_IN_SPECTRAL.19.pdf; https://boris.unibe.ch/153855/ |
| Rights: |
info:eu-repo/semantics/restrictedAccess |
| Accession Number: |
edsbas.348DE350 |
| Database: |
BASE |